echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > To Ling Pharmaceutical Lianhua Qing plague capsules to obtain the Mongolian drug registration approval

    To Ling Pharmaceutical Lianhua Qing plague capsules to obtain the Mongolian drug registration approval

    • Last Update: 2021-01-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Lianhua Qing plague products for the national basic drug catalog and national health insurance catalogue (Class A) varieties, mainly used for cold, influenza-related diseases treatment.
    announcement, Lianhua Qing plague products have been repeatedly by the National Health And Health Commission, the State Administration of Traditional Chinese Medicine included in the cold, influenza-related disease diagnosis and treatment program.
    2020 Lianhua Qing plague capsules/particles are listed as the National Health And Health Commission and the State Administration of Traditional Chinese Medicine jointly issued the "new coronavirus pneumonia diagnosis and treatment program" (trial 4/5/6/7/8 version) recommended medication.
    April 12, 2020, the State Drug Administration approved lianhua Qing plague capsules/particles to add a new adaptation of "new coronavirus pneumonia light, common type" on the basis of the original approved adaptation.
    2019, The company achieved operating income of 1.703 billion yuan, accounting for 29.24% of its total operating income.
    the first three quarters of 2020, Lianhua Qing plague products achieved operating income of 2.871 billion yuan, accounting for 44.52 percent of total operating income.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.